Twist launches synthetic RNA capsules

By The Science Advisory Board staff writers

March 22, 2022 -- Twist Bioscience has launched synthetic RNA positive controls for SARS-CoV-2 encapsulated in proprietary stainless steel minicapsules provided by Imagene SA.

The design enables enhanced storage and transportation and cost-efficiency. The synthetic controls, which are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified.

Imagene stainless steel minicapsule. Image courtesy of Imagene.
Twist, Kriya partner to discover novel antibodies
Twist Bioscience and Kriya Therapeutics have entered into an antibody discovery agreement for antibodies delivered using adeno-associated viral gene therapy...
Twist Bioscience, Eleven Therapeutics create replicon for antiviral development
Twist Bioscience and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication and antiviral drug screening...
Twist Bioscience partners with Artisan Bio on next-gen cell therapies
Twist Bioscience and Artisan Bio have entered into a collaboration agreement to discover novel antibodies against five undisclosed targets, with an option...
Twist Bioscience develops innovative enzymatic DNA synthesis process
Twist Bioscience has developed an innovative, low-cost, scarless, and scalable enzymatic DNA synthesis process. With these comprehensive capabilities...
Sosei Heptares enters agreement with Twist Bioscience
Twist Bioscience and Sosei Group have formed a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors identified...

Copyright © 2022 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter